GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults.
about
New Insights into the Generation of CD4 Memory May Shape Future Vaccine Strategies for InfluenzaT-Cell Immunity to Influenza in Older Adults: A Pathophysiological Framework for Development of More Effective VaccinesAge-dependent dysregulation of innate immunityThe unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccinesA novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent modelsClinical vaccine development for H5N1 influenza.Impaired heterologous immunity in aged ferrets during sequential influenza A H1N1 infection.In vitro evaluation of TLR4 agonist activity: formulation effects.A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine RegimensCD8+ memory T-cell inflation renders compromised CD4+ T-cell-dependent CD8+ T-cell immunity via naïve T-cell anergy.Exploiting the critical perioperative period to improve long-term cancer outcomesAging of the T cell compartment in mice and humans: from no naive expectations to foggy memories.A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate.IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.Trial Watch: Peptide-based anticancer vaccines.Vaccine self-assembling immune matrix is a new delivery platform that enhances immune responses to recombinant HBsAg in micePreclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors.From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.A Novel Class of Small Molecule Agonists with Preference for Human over Mouse TLR4 ActivationSm-p80-based schistosomiasis vaccine mediated epistatic interactions identified potential immune signatures for vaccine efficacy in mice and baboons.Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndromeVaccine strategies to enhance immune responses in the aged.Immunosenescence-Related Transcriptomic and Immunologic Changes in Older Individuals Following Influenza Vaccination.IL-2 and IL-6 cooperate to enhance the generation of influenza-specific CD8 T cells responding to live influenza virus in aged mice and humans.Adjuvants for human vaccines.Aged-related shifts in T cell homeostasis lead to intrinsic T cell defects.Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines.Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults.Molecular characteristics and potential therapeutic targets in Merkel cell carcinoma.Vaccinology: The art of putting together the right ingredientsAn overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection.Personalized vaccinology: A review.Cellular immune responses of older adults to four influenza vaccines: Results of a randomized, controlled comparison.IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.CpG-mediated augmentation of CD8+ T-cell responses in mice is attenuated by a water-in-oil emulsion (Montanide ISA-51) but enhanced by an oil-in-water emulsion (IDRI SE).Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants.The stimulatory effect of the TLR4-mediated adjuvant glucopyranosyl lipid A is well preserved in old age.Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon?
P2860
Q26752546-FD4E1B76-EA45-450A-BB0A-B5530E9BAA8EQ26768539-4DAA9AA1-E6B6-4A30-ACE6-7BED8A73B93EQ27022410-FAE89A72-3775-42A7-A71B-26E7C30ACFC3Q27025076-4BEF2BB5-F96A-4B02-A565-E08DEE32259BQ27312129-33077E07-D295-4989-9F65-5F7F1F412BA0Q30222083-C9403CF7-98DD-4FC5-8828-0EEA9532B7C7Q30365379-67F40FC1-7A2D-4DF3-B9D0-14C2B18439E8Q30561113-A25FEB41-4910-40E2-A135-FE9CC24BF1EEQ33720317-75D3368F-4145-461B-B9C4-6974D4DF4B80Q33820931-F04F7A5B-7079-4B3F-8FB1-FF6723A46AC6Q33871661-DC99E60E-C511-4E4B-A086-C91A809C7761Q34147526-BF41B931-4C48-494D-B71B-CB097B5FC34BQ34232909-D4026049-4A67-486B-BC22-D5F05444CB4CQ34400813-43EE9C5D-E474-47FC-9BB3-7D4FCF33CF89Q34483345-C0727828-B453-4BC2-B574-94D01DD4DC1AQ35122785-7A005A85-A53A-4492-90BE-A401018CDF21Q35412152-E844B83B-72A5-43F4-B2AA-85DEC2485743Q35809113-9D669B69-2392-41E2-84F4-A4609FE5E4A0Q35836140-F178A476-AE17-402B-AE1B-3694D2BC3839Q36162709-572E24FF-3234-4EDE-819F-ED21B7566BF0Q36278786-788367C3-BA22-48D6-9BF9-97D3B04DDA6EQ36650501-C08FB6E8-9CA7-459B-B4C4-81C57577B8CEQ37179398-517A2092-0DBB-474F-AE8B-9F45080C270CQ37385591-1CD404AE-17D1-4380-A0D4-E17CF5CAC37BQ37457451-191311B0-1608-4946-B6DB-80E52A5AE6EEQ38004229-C345CE7D-01BE-4CE8-BCC0-3471EC879DBAQ38008087-1A581D71-084E-46C9-A78A-8D2C195B4BA3Q38032881-B432B3BD-E1F1-4972-8308-7540366CF582Q38124061-B690A1D2-B34C-4F78-9F95-B629A2D0249DQ38714104-FABD325A-8864-41FA-BEE7-9765FD071F21Q38922448-4791D339-F4CC-43A8-8C91-B31BE344573CQ39174792-AFA0221F-E106-4143-84CD-90FFF6AE5607Q39310460-89D252D1-E0EC-4A1F-B539-B8CA61632448Q40107665-56D7B4C7-9701-43B6-A37E-6C9B35267069Q40151447-E27B514E-B879-4EA5-A53C-26C623ED3114Q40476014-5C91C0E4-482D-420B-A14E-4E6BFE53FE85Q40724264-B565C67F-A58F-443F-BBC3-8F1A9D465893Q41151191-44DA58FA-F1E7-4896-995E-84441F68DF78Q41246444-0B34B657-ADED-4AD2-B961-18A6FB97C39AQ41458291-E7063800-BA28-4E3A-8F5B-9531FC7D2F3F
P2860
GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
GLA-SE, a synthetic toll-like ...... uenza vaccine in older adults.
@ast
GLA-SE, a synthetic toll-like ...... uenza vaccine in older adults.
@en
type
label
GLA-SE, a synthetic toll-like ...... uenza vaccine in older adults.
@ast
GLA-SE, a synthetic toll-like ...... uenza vaccine in older adults.
@en
prefLabel
GLA-SE, a synthetic toll-like ...... uenza vaccine in older adults.
@ast
GLA-SE, a synthetic toll-like ...... uenza vaccine in older adults.
@en
P2093
P2860
P50
P356
P1476
GLA-SE, a synthetic toll-like ...... uenza vaccine in older adults.
@en
P2093
Anke L W Huckriede
Beth Gentleman
Hayedeh Behzad
Jan C Wilschut
Janet E McElhaney
Laura Haynes
P2860
P304
P356
10.1093/INFDIS/JIR769
P407
P577
2011-12-05T00:00:00Z